Due to low enrollment, this study was terminated early.

This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up. Approximately 60 participants will be enrolled, and omalizumab will be dosed according to the approved United States Package Insert (USPI) dosing table.

Inclusion Criteria:

• Physician-diagnosed asthma for at least 12 months prior to screening
• Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen
• Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period
• Able to safely complete incremental exercise tolerance at screening
• Pre-bronchodilator FEV1 of 40%-80% of predicted at screening
• Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry
• On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (≥)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for ≥3 months prior to screening
• Uncontrolled asthma during the screening period, defined as an ACQ-5 ≥0.75 score
• Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug.

Exclusion Criteria:

• Known history of anaphylaxis/hypersensitivity to omalizumab
• Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening
• Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening
• Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period
• Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period
• Isolated diagnosis of exercise induced asthma without chronic symptoms
• History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma
• Current malignancy or history of malignancy within 5 years prior to screening
• Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions
• Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening
• Current smoker or past smoker with >10 pack years
• Known HIV infection at screening
• Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening
• Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening
• Active tuberculosis requiring treatment within 12 months prior to screening
• History of alcohol, drug, or chemical abuse within 6 months of screening

Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research\_and\_development/who\_we\_are\_how\_we\_work/clinical\_trials/our\_commitment\_to\_data\_sharing.htm).

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.